UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) June 25, 2024

TECTONIC THERAPEUTIC, INC.
(Exact name of registrant as specified in its charter)

Delaware	**001-38537**	**81-0710585**
(State or other jurisdiction of incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

490 Arsenal Way, Suite 210 **Watertown, MA**	**02472**
(Address of principal executive offices)	**(Zip Code)**

(339) 666-3320
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2.):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	TECX	Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01. Regulation FD Disclosure.

Tectonic Therapeutic, Inc. (the "Company") has updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the updated corporate presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. Investors may access the presentation by visiting the "Events & Presentations" section of the Company's investor website at https://investors.tectonictx.com.

The information furnished under this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any of the Company's filings with the Securities and Exchange Commission, regardless of any general incorporation language in such a filing.

Item 8.01 Other Events.

Proposed TX000045 ("TX45") Phase 2 Trial Design

As previously disclosed, the Company plans to initiate its Phase 2 randomized, placebo-controlled, double-blind proof-of-concept clinical trial to evaluate TX45 in patients with Group 2 Pulmonary Hypertension ("PH") in the setting of Heart Failure with Preserved Ejection Fraction ("HFpEF") in the second half of 2024.

The Phase 2 clinical trial is expected to be conducted globally, including at clinical trial sites in the United States, Europe, Eastern Europe and Australia. This trial is designed to enrich for patients with an increased pulmonary vascular resistance of greater than 3 on baseline right heart catheterization with the goal of evaluating efficacy in both Combined pre-and post-capillary Pulmonary Hypertension as well as the whole Group 2 PH population with HFpEF. The Company currently expects that approximately 180 subjects will enter the trial. Each subject will be randomized to one of two treatment arms or a placebo arm. The treatment period will last for 24 weeks and there will be a follow-up evaluation 8 weeks after the last dose.

Forward-Looking Statements

Statements contained in this Current Report on Form 8-K regarding matters that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Company may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "designed," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should" or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include but are not limited to, expectations regarding the initiation, design, protocol and timing of the Company's proposed Phase 2 clinical trial of Group 2 PH in the setting of HFpEF. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that contribute to the uncertain nature of the forward-looking statements include potential unforeseen events during clinical trials could cause delays or other adverse consequences; risks relating to the regulatory approval process; success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; the Company's product candidates may cause serious adverse side effects; the Company's reliance on third parties, including for the manufacture of materials for its research programs, preclinical and clinical studies; the ability of the Company's need for additional funding, which may not be available; the impact of macroeconomic conditions, including the conflict in Ukraine and the conflict in the Middle East, heightened inflation and uncertain credit and financial markets, on the Company's business, clinical trials and financial position; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; and unexpected litigation or other disputes. Other factors that may cause the Company's actual results to differ from those expressed or implied in the forward-looking statements in this press release are identified under the heading "Risk Factors" in the final prospectus on Form 424(b)(3) filed by the Company with the SEC on May 3, 2024, and in other filings that the Company makes and will make with the SEC in the future. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Corporate Presentation dated June 2024.
104	Cover Page Interactive Data File (formatted as Inline XBRL).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TECTONIC THERAPEUTIC, INC.

Date: June 25, 2024

By: /s/ Daniel Lochner
Daniel Lochner
Chief Financial Officer

Exhibit 99.1


Transforming and Innovating the Discovery and Development of Novel, Class Leading GPCR-Targeted Therapies
June 2024
TECTONIC Therapeutic

DISCLAIMER

Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as "anticipates," "believes," "expects," "intends," "plans," "potential," "projects," "would" and "future" or similar expressions are intended to identify forward-looking statements. Each of these forward-looking statements involves substantial risks and uncertainties that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements. Forward-looking statements contained in this presentation include, but are not limited to, statements regarding: the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of our product candidates, including the ongoing Phase 1a/b clinical trial for TX45, in Group 2 Pulmonary Hypertension and initiation of proposed Phase 2 clinical trial; candidate selection for our second program in HHT; the expected timing of program updates and data disclosures; the timing of filing INDs and other regulatory documents; the timing and likelihood of seeking regulatory approval for our product candidates including TX45; the competitive landscape for our product candidates; our ability to identify and develop additional product candidates; and our estimates regarding expenses, future revenue, capital requirements, cash runway and needs for additional financing.

These forward-looking statements reflect our current beliefs and expectations. Many factors may cause differences between current expectations and actual results, including the early stage of our development efforts; success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidates; clinical site activation rates or clinical trial enrollment rates that are lower than expected; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; the impact of macroeconomic conditions, including the conflict in Ukraine and the conflict in the Middle East, heightened inflation and uncertain credit and financial markets, on our business, clinical trials and financial position; and unexpected litigation or other disputes. These and other risks are described more fully in our filings with the Securities and Exchange Commission ("SEC"), including the risks detailed in the prospectus filed with the SEC pursuant to Rule 424(b)(3) on May 3, 2024, and other documents we subsequently filed with or furnished to the SEC. All forward-looking statements contained in this presentation speak only as of the date on which they were made. Except as required by law, we assume no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. Neither we nor any other person makes any representation as to the accuracy or completeness of such data or undertakes any obligation to update such data after the date of this presentation. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk.

Agenda

I. Company Overview
II. GEODe™ Platform
III. TX45 Relaxin in Group 2 Pulmonary Hypertension
    i. Overview of Target and Indication
    ii. Patient Journey
    iii. Clinical Data
    iv. Preclinical Data
    v. Clinical Program
IV. HHT Program
V. Summary

Tectonic Therapeutic – Transforming the Discovery of Novel GPCR-Targeted Therapies, Innovating in Their Development

Validated GEODe™ Platform

- Validated platform to discover and optimize biologics that target GPCRs
- Prioritizing high value GPCR targets, where small molecules are not the right modality

Phase 1 Best-In-Class Relaxin Agonist for PH, First-In-Class HHT Program

- First two assets address indications with no approved therapy
  1. RXFP1 agonist - potential therapy for Group 2 PH[1] in HFpEF[2]
     - >600,000 Patients in US alone (>20 times PAH)
     - Initial Phase 1a PK/PD data demonstrated activity and favorable PK with potential for monthly dosing; full data mid-2024
     - Phase 1b hemodynamic proof of concept expected in 2025, randomized Phase 2 data expected in 2026
  2. GPCR antagonist antibody addressing hereditary hemorrhagic telangiectasia (HHT)

Team with a Track Record of "Firsts"

- Team with extensive track record of drug discovery and development success, resulting in 20 "first" approvals across multiple therapeutic areas

Reverse Merger Closed June 2024

- Well capitalized by a syndicate of leading institutional funds
- **$181M[3] post close expected to provide runway into mid-2027**

[1]Pulmonary Hypertension; [2]Heart Failure with Preserved Ejection Fraction; [3]At transaction close (6/20/24), cash, cash equivalents and investments of approximately $181 million, before payment of final transaction-related expenses, is expected to fund current operational plans into mid-2027

TECTONIC Therapeutic

This Accomplished Team Has Delivered for Patients and Investors

Alise Reicin, M.D.
CEO, Director

Celgene · MERCK · Columbia University · KEYTRUDA (pembrolizumab)

Daniel Lochner
CFO

VIATRIS · Goldman Sachs · OYSTER POINT · Columbia University

Peter McNamara, Ph.D.
CSO

NOVARTIS · GNF · Penn · BRAFTOVI (encorafenib)

Anthony Muslin, M.D.
CDO

NOVARTIS · SANOFI · Washington University in St. Louis School of Medicine · Entresto (sacubitril/valsartan) tablets

Marcella Ruddy, M.D.
CMO

REGENERON · MERCK · Alnylam · MGH 1811 · DUPIXENT (dupilumab) injection

Marc Schwabish, Ph.D.
CBO

Fusion · Bayer · Eisai · RBS

Timothy Springer, Ph.D.
Co-Founder

FOUNDED MULTIPLE SUCCESSFUL COMPANIES

LeukoSite · moderna · MORPHIC · SEISMIC · Scholar Rock

2022 Lasker Award

Andrew Kruse, Ph.D.
Co-Founder

GPCR EXPERT, FORBES "30 under 30"

HARVARD MEDICAL SCHOOL · SEISMIC

Multiple Awards and Fellowships
(Biomedical Research, NIH, Amgen, Sloan Research)

TECTONIC Therapeutic

Team Track Record: >20 1st Approvals with >$50B In Annual Sales

1st approvals and indication expansions shown below

ONCOLOGY/ IO

- KEYTRUDA (pembrolizumab)
- Abecma (idecabtagene vicleucel)
- BAVENCIO (avelumab)
- Breyanzi (lisocabtagene maraleucel)
- Campath (Alemtuzumab)
- BRAFTOVI (encorafenib)
- VELCADE (bortezomib)
- ZYKADIA (ceritinib)
- TEPMETKO (tepotinib)
- Odomzo (sonidegib)

IMMUNOLOGY/ INFLAMMATION

- DUPIXENT (dupilumab)
- Amevive (alefacept)
- Entyvio (vedolizumab)
- MAVENCLAD (cladribine tablets 10 mg)
- ARCOXIA (etoricoxib)
- MAYZENT (siponimod)
- Simponi (golimumab)
- Remicade (INFLIXIMAB)
- ZEPOSIA (ozanimod)
- RAPTIVA (efalizumab)
- VIOXX (rofecoxib, MSD)

CARDIO/ METABOLISM

- Entresto (sacubitril/valsartan) tablets
- Praluent (alirocumab) Injection
- CAMZYOS (mavacamten) capsules

RESPIRATORY / ALLERGY

- DUPIXENT (dupilumab)
- Claritin
- SINGULAIR
- Nasonex
- GRASTEK (Timothy Grass Pollen Allergen Extract Tablet for Sublingual Use 2800 BAU)

OTHER

- Reblozyl (luspatercept-aamt) for injection 25mg • 75mg
- INREBIC
- EMEND (Aprepitant)

Biologics Offer Advantages Over Small Molecules in Targeting GPCRs in Multiple Settings



- >470 Approved drugs (~33% of all)
- >$180B in annual sales
- Predominantly small molecules
- Only 3 are antibodies

When difficult to drug with small molecules
Biologic captures complexity of ligand / receptor engagement

If target site similar to domains of different proteins
Biologic minimizes off target binding to improve safety / tolerability

If use case requires tissue /compartment targeting
Engineer biologic to target or exclude compartment as needed

When multi-modal action needed
Bispecific approach enables dual target engagement

(*) Hauser, A.S. et al., Cell, 2018 Jan 11; 172(1-2): 41–54.e19.

* 18% = 100% - 12% (approved drug targets) – 50% (sensory) – 20% (non-sensory, orphan)

TECTONIC Therapeutic

Our Unique Pipeline Opportunities are Enabled by Biologic Targeting of GPCRs

GROUP 2 PULMONARY HYPERTENSION (Group 2 PH)

Potential Best-in-Class

RXFP1 Agonist[1]

Supporting clinical data



HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)

First in Class & Indication

GPCR Antagonist[2] (anti-angiogenic)

Target pathway linked to disease genetics



FIBROSIS

Bi-specific Approach

GPCR Modulator[2] (anti-fibrotic)

Supporting clinical data for one component of bispecific

Scale of POC studies: ~50-200 patients per indication
3-6 months treatment

1. Fusion protein – lead molecule in-licensed from Harvard U., optimized using GEODe platform
2. GPCR targeted therapeutics discovered internally using GEODe platform

Pipeline of GPCR-Targeted Biologics with Multiple Potential Value Infection Points Ahea

Development programs include first-in-indication opportunities*



(1) Pulmonary Hypertension

GEODe™ PLATFORM

Proprietary, validated platform, enables reproducible discovery and optimization of GPCR targeted biologics


GEODe
Solving Key Challenges in GPCR Targeted Biologics Discovery
Challenges
RETAIN
endogenous GPCR structure to enable screening against relevant form of receptor
PURIFY
target in sufficient quantities to power screening campaign
INDUCE
immune response to human GPCR in animals if immunization strategy is pursued
STABILIZE
receptor in active conformation to enable agonist discovery
GEODe™ Platform Features Designed for Success
1.
Receptor Engineering, and Purification Technology
delivers abundant receptor reagent in native conformation
2.
In-vitro Yeast Display Libraries
provide high-diversity, without immune editing
3.
Protein Engineering
Optimize protein pharmacology
Engineer antigen formats to enable screening for agonists or antagonists as needed

Proprietary GEODe™ platform spans three enabling technologies to identify and optimize potent GPCR targeted biologics

1. EXPRESSION AND PURIFICATION TECHNOLOGY

Produce Sufficient Quantities and Stabilize Them in the Correct Conformation

2. IN-VITRO YEAST DISPLAY LIBRARIES

Efficiently Screen Diverse Antibody Libraries Against GPCRs



3. PROTEIN ENGINEERING

- **Optimize Protein Pharmacology**
- **Engineer Proprietary Scaffolds for Agonist Discovery**



Large toolbox of biochemical methods, engineering tools, and assays

TECTONIC Therapeutic

GEODe™ Platform Discovery Capabilities Deliver Selective, Ligand Competitive Orthosteric Antagonists

PURIFIED ANTIBODIES ARE FUNCTIONAL ANTAGONISTS*



OPTIMIZATION IMPROVES ORIGINAL POTENCY BY ~20X



SELECTIVE (NO EFFECT ON OFF-TARGET GPCR)



**Latest generation proprietary libraries delivering initial hits with >10X potency*

Our Proprietary Antigen Formats Enable Screening for Biologics with Agonist Activity

Design of Our Proprietary Gα Mimetics Is Driven by the Latest in Machine Learning and Energy Prediction Algorithms



Ongoing enhancement of our ability to screen for biologics with agonist activity

End-to-end Capabilities in Place at Tectonic for Continued Discovery of Optimal DCs

TECTONIC Therapeutic

Suite of Ab Discovery, Optimization and Characterization Capabilities



TX45: Fc-RELAXIN FUSION PROTEIN

RXFP1 agonist with differentiated profile

Hemodynamic and Anti-fibrotic Properties of Relaxin Demonstrated by its Role in Pregnancy

Pharmacology

AGONIST

Natural Ligand of RXFP1 Receptor

No RXFP1 internalization from relaxin agonism → no desensitization with chronic therapy

Relaxin upregulated in pregnancy



Local resolution cryo-EM map of full-length RXFP1–Gs complex
BioRxiv: https://doi.org/10.1101/2022.01.22.477343

Facilitates Gestation

PULMONARY AND SYSTEMIC VASODILATOR

Increases cardiac output to accommodate the increased demand from developing fetus

ANTIFIBROTIC

Prepares musculoskeletal tissues for pregnancy and childbirth

The First Recombinant Relaxin (serelaxin) Demonstrated Safety and Benefit in Acute Heart Failure (AHF) in Trials of >11,000 Patient

-Note: trials only included a two-day relaxin infusion

Study (WHF Day 5)	Relative Risk [95% CI]	N(drug)	N(pbo)
Pre-RELAX AHF	0.56 [0.22 – 1.45]	42	61
RELAX-AHF	0.54 [0.37 – 0.78]	581	580
RELAX-AHF-2	0.90 [0.76 – 1.07]	3274	3271
RELAX-AHF-EU	0.71 [0.52 – 0.98]	1756	894
RELAX-AHF-ASIA	0.42 [0.21 – 0.84]	437	433
Meta Analysis	**0.77 [0.67 – 0.89] p = 0.0002**	6090*	5239

Effects of serelaxin on worsening heart failure (WHF) – fixed-effect (FE) meta-analysis; serelaxin 30 µg/kg/day vs. placebo,. CI, confidence interval.

PK limitations of relaxin a major hurdle to its development for chronic diseases

Our GEODe Protein Engineering capabilities address this challenge

- One of two pivotal studies included in meta-analysis, RELAX-AHF-2, failed to achieve the co-primary endpoints, and we believe that two factors contributed to this outcome
  - It was ambitious to expect that a two-day infusion of serelaxin, with its short half-life and mechanism of action, would demonstrate clinical benefit at day 5 and, more puzzlingly at 6 months
  - Operational challenges with patient enrollment may also have had an impact

*Teerlink J.R. et al. Eur. J. Heart Fail. 2019; 22: 315-329; patients from RELAX-AHF-JP (N=30 total) not listed in table

TECTONIC Therapeutic

TX45 is Engineered to Solve a Critical PK Problem Observed with Other Relaxin Molecules

Relaxin has **very short *in vivo* half-life** Fc-fusion needed to improve PK

Relaxin Fc-fusions **have steep decline in exposure after dosing** (>90%) because of glycocalyx binding due to high pI[1]

Engineering TX45 to **reduce net positive charge (and lower pI) prevents rapid clearance**

TX45 EXHIBITS SUPERIOR PROFILE vs. PARENT COMPOUND AND COMPARATOR[2] MOLECULE[3]

Preclinical Rat Pharmacokinetic Data



1. Isoelectric Point
2. High pI Fc-relaxin fusion protein described in literature
3. Source: Tectonic internal data

TX45 Reflects Significant Protein Engineering to Optimize Its Pharmacology

TX45 results in ~10x greater *in vivo* potency over comparator[1] molecule than predicted based on PK and *in vitro* activity[2] – potentially from reduced trapping of drug in glycocalyx, resulting in increased free drug available to activate RXFP1 in tissues





1. High pI Fc-relaxin fusion protein described in literature
2. ~0.03 mpk of TX45 has similar efficacy as 0.3 mpk of Comparator
3. Source: Tectonic internal data

TECTONIC Therapeutic

TX45 – Optimized RXFP1 Agonist for Group 2 PH in HFpEF

✓ **Potential Best-in-Class Relaxin Agonist with Optimized PK**	• Protein engineering has extended pharmacologic half-life to support monthly dosing
✓ **High Unmet Need in Group 2 PH with HFpEF[1]**	• No approved therapy • >600,000 patients in US • High 5-year high mortality
✓ **Mechanism may be Ideal to Address Group 2 PH**	• Pulmonary + systemic vasodilation, cardiac relaxation • Reversal of fibrosis in pulmonary vasculature and heart • Anti-inflammatory
✓ **Supporting Clinical and Pre-clinical Data**	• Hemodynamic benefit in studies of serelaxin in AHF • Clear benefit observed with TX45 in rodent PH and CHF models
✓ **Streamlined Development Strategy**	• No outcome study needed • Enrichment strategy for CpcPH where there is greatest unmet need • Enables potential early launch relative to congestive heart failure
✓ **Potential to Expand Indications**	• Other PH Groups, Heart failure, renal disease

1. Heart Failure with preserved Ejection Fraction

Pulmonary Hypertension Consists of 5 Distinct Diseases

Group 2 PH is of Greatest Interest for TX45's Initial Indication

Group 1 ("PAH") (~25,000[1])	Group 2 (>600,000[1])	Group 3	Group 4 ("CTEPH")	Group 5 (Misc.)
• Idiopathic • Hereditary • Connective tissue disease-associated • Congenital heart disease-associated • Drug-induced	• **Due to left heart disease (HFpEF, HFrEF) or valvular heart disease** • **CAD, HTN, T2DM[2], high cholesterol are risk factors** • **Two Subtypes: CpcPH / IpcPH**	• Due to lung disease or hypoxia • May be due to COPD, interstitial lung disease (i.e., IPF) or obstructive sleep apnea	• Chronic thrombo-embolic pulmonary hypertension –i.e., as a consequence of blood clots	• Miscellaneous group with causes unclear or multiple underlying factors

1. US Prevalence
2. CAD: Coronary Artery Disease, HTN: Hypertension, T2DM: Type 2 Diabetes Mellitus

Nat. Pul. Hypertension Unit, Ireland

Our Focus is on the Group 2 PH Subset of Heart Failure with Preserved EF (HFpEF)

Clinical Program Designed to Enable Evaluation of Efficacy in Overall Population and CpCPH



IpcPH (**I**solated, **p**ost **c**apillary **PH**)

Increased Left Ventricle Filling Pressures
↓
Increased Pulmonary Venous Pressures
↓
Passive Pressure Backflow
↓
Pulmonary Hypertension



CpcPH (**C**ombined, **p**re- and post **c**apillary **PH**)

Chronic PH and/or Other Drivers
↓
Permanent Vascular Changes, e.g. Pulmonary Artery Remodeling
↓
Increased Vascular Resistance
↓
Right Heart Failure



1. US prevalence numbers. Estimates based on data from
2. Kapelios, C. et al., Cardiac Failure Review 2023;9:e14
3. Sera F. et al. Heart 2023;109:626–633

Group 2 PH: Patient Journey

Key Hemodynamic Measures in Pulmonary Hypertension

Measure	Definition	Detection Method(s) / Formulas	Clinical Significance
mPAP Mean Pulmonary Arterial Pressure (mm Hg)	**Fluid pressure in the lung arteries**	Directly measured by RHC sPAP estimated by echo	**Key parameter for diagnosing pulmonary hypertension of all causes (Groups I-V)**
PVR Pulmonary Vascular Resistance (Wood Units)	**Resistance to blood flow in pulmonary arteries ("narrowness of pipes")**	Calculated from mPAP, PCWP, and CO obtained by RHC PVR = (mPAP-PCWP)/CO	**Provides information about disease/narrowing specifically in pulmonary arteries**
PCWP Pulmonary Capillary Wedge Pressure (mm Hg)	**Fluid pressure in lung capillaries – measure of left atrial pressure**	Directly measured by RHC	**Used to assess left ventricular filling abnormalities – elevated in left sided heart failure ("hard to fill pump")**
CO Cardiac Output (L / min)	**Amount of blood pumped per unit time**	CO directly measured by RHC thermodilution	**CO is a key measure of heart function and is depressed in heart failure**

Treatment of Pulmonary Hypertension (PH) in the Setting of Heart Failure with Preserved Ejection Fraction (HFpEF)



Relaxin Multimodal MOA Addresses Pathways Implicated in Group 2 PH Pathophysiology



Mechanisms Implicated in Group 2 PH

1. Activation of ET-1 pathway(*)
2. Reduced NO pathway activity(*)
3. Activation of TGFβ pathway

(*) Most active in CpcPH subset

Effects of RXFP1 Activation by Relaxin

- ✓ Pulmonary and systemic arterial vasodilation
- ✓ Favorable remodeling: anti-fibrotic effect in heart and pulmonary vasculature
- ✓ Anti-inflammatory

TECTONIC Therapeutic

Relaxation and Anti-Fibrotic Effects of Relaxin Have Potential for Disease Modification in Group 2 PH

- Heart, and vascular dysfunction contribute to disease pathology
- Renal dysfunction also present in many of these patients

CHARACTERISTICS OF GROUP 2 PH	IpcPH	CpcPH	ANTICIPATED RELAXIN EFFECTS
Pulmonary artery narrowing, thickening, stiffening, fibrotic remodeling		✓	Pulmonary Vasodilation Anti-inflammatory, anti-fibrotic
Right Ventricular Dysfunction	✓	✓	Right ventricular remodeling
Thickening and stiffening of Left Ventricle	✓	✓	Peripheral vasodilation, cardiac relaxation, left ventricular remodeling
Compromised kidney function	✓	✓	Improvement in kidney function

Reducing pulmonary pressures and improvement of left heart function are both key to providing efficacy

Group 2 PH vs. PAH

- Significant opportunity for a first-in-indication therapy
- Highly motivated physicians and patients

US PREVALENCE >> PAH



Multi-$ Billion Market Opportunity

>$4 Billion Market in US Today[5]

5 YEAR SURVIVAL ≤ PAH[6]



NO THERAPEUTIC OPTIONS

Group 2 PH	PAH
No approved therapies ... Limited pipeline *PAH Drugs have not demonstrated convincing efficacy in Group 2 PH with the exception of PDE5i in CpcPH*	Multiple drugs/ mechanisms approved ET1R antagonists PDE5 inhibitors GC stimulators Prostacyclins ACTRII-Trap

1. US prevalence numbers. Estimates based on data from
2. Kapelios, C. et al., Cardiac Failure Review 2023;9:e14
3. Sera F. et al. Heart 2023;109:626–633
4. www.pahinitiative.com
5. GlobalData
6. Caravita S. et al. https://doi.org/10.1371/journal.pone.0199164; Gall H. et al The Journal of Heart and Lung Transplantation, Vol 36, No 9, September 2017; estimates from synthesis of different studies

PDE5 Inhibitors Affect Only One of Several Pathways Addressed by Relaxin



TX45 anticipated to be effective in both Cpc-PH and Ipc-PH because it targets additional anti-fibrotic and anti-inflammatory mechanisms on top of activation of the NO pathway

1. Guazzi et al. 2011
2. Belyavskiy et al. 2020
3. Kramer et al. 2019

PDE5 Inhibitors Show Significant Benefit in CpcPH and HFpEF Despite Limited Mechanism of Action Compared with Relaxin

Expected to Increase POS of Relaxin in HFpEF and CpcPH

PDE5i LOWERS PVR(1)



PDE5i PRODUCES IMPROVEMENTS IN 6MWT (2)



PDE5i TREATMENT DECREASES HOSPITALIZATIONS (3)



1. Guazzi et al. 2011
2. Belyavskiy et al. 2020
3. Kramer et al. 2019

Relaxin Improves Hemodynamics in Heart Failure

Balanced pulmonary and peripheral vasodilation, and improved heart function (decreased PCWP) relevant to Group 2 PH

- Panels: serelaxin infusion for 20hrs in Acute Heart Failure patients with elevated pulmonary artery pressure (PAP) **rapidly lowered mPAP, pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), pulmonary capillary wedge pressure (PCWP)*,****
- Not shown: serelaxin also improved **right atrial pressures (RAP), and renal function***
- In a similar study in patients with chronic CHF, **a reduction in PCWP and an increase in cardiac output** was demonstrated**



*Ponikowski P, et al. Eur. Heart J. 2014, **Dschietzig T, et. Al. Ann NY Acad Sci 2009
** Diuretics were allowed after the first 8 hours

TECTONIC Therapeutic

TX45 and Other Relaxin Preclinical Data

Preclinical validation
Anti-fibrotic effects of relaxin observable across broad range of studies

TX45 Efficacy in Monocrotaline-Induced Model of Pulmonary Hypertension in Rats

TX45 Significantly Reduces Right Ventricular Systolic Pressure, Fulton's Index and Muscularization of Small Pulmonary Arteries in Tx Model of PH

Improved Pulmonary Hemodynamics



Reduced Cardiac Hypertrophy



Reduced Histological Inflammation



Reduced Pulmonary Arterial Muscularization



TX45 Significantly Reduces Collagen and TNFa levels in Mouse UUO Model of Renal Fibrosis







* Dotted red line defines the cortex region

TX45 Reduces Cardiac Hypertrophy and Fibrosis in the Mouse Isoproterenol Induction Model



Relaxin Prevents Diastolic Dysfunction in a Model of HFpEF and Reverse Cardiac Fibrosis

Relaxin Prevents TAC (transverse aortic constriction) -Induced Cardiac Diastolic Dysfunction in Rats & Reverses Diabetes-Induced Cardiac Fibrosis and Diastolic Dysfunction in mRen-2 Rats.

Human relaxin-2 Improves Diastolic Dysfunction

gene therapy administered with 28 days follow-up
(Shuai X.X. et al. 2016)



Human relaxin-2 reverses cardiac fibrosis

2 wk infusion in STZ-treated diabetic/HTN mRen-2 rats
(Samuel C.S. et al. 2008)



* GFP = green fluorescent protein (adenovirus used as negative control)

TECTONIC Therapeutic

Additional Anti-Fibrotic Effects of Relaxin Demonstrated in Preclinical Animal Models of Heart Failure

In other rodent models of heart failure, Relaxin has been shown to also:

- ✓**Inhibit** TGFβ or ANG-II induced collagen synthesis in cardiac fibroblasts[1]
- ✓**Prevent** interstitial and perivascular fibrosis, with effect superior to enalapril[2]
- ✓**Prevent** diastolic dysfunction[3]
- ✓**Prevent** and **Reverse** cardiac hypertrophy[3]
- ✓**Reverse** cardiac inflammatory gene expression[4]



Findings consistent across models and studies published by different investigators

1. **Relaxin knockout** model of cardiac fibrosis (mouse) - *Samuel C.S. et al. 2004*
2. **Isoproterenol infusion** model of heart failure (mouse) - *Samuel C.S. et al. 2014*
3. **Transverse aortic constriction** model of HFpEF (rat) - *Shuai X.X. et al. 2016, Lapinskas T. et al. 2020*
4. **Aging-induced** cardiac inflammation (rat)- *Martin B. et al. 2018*

TX45 Clinical Program and Preliminary Phase 1 Data

TX45 Development Program Overview

Planned readouts in mid-2024, 2025, 2026



RHC: Right Heart Catheter
mPAP: Mean Pulmonary Arterial Pressure
PVR: Pulmonary Vascular Resistance
CO: Cardiac Output
6MTW: 6-Minute Walk Test

Development Plan Reviewed with FDA via Pre IND

TECTONIC Therapeutic

TX45 Single Ascending Dose Study : Summary of preliminary data[1]

- **Well tolerated with minimal adverse events, no drug-related SAEs**
- **Pharmacokinetics**
  - Low intersubject variability in serum concentrations (≤ 20%)
  - No evidence of immune mediated clearance
- **Pharmacodynamics from 0.3 mg/kg cohort (lowest dose)**
  - 30% increase in renal plasma flow on Day 2 post dose persisting at least until Day 8 post dose
  - Magnitude of effect consistent with serelaxin's effect
  - **Meets "go criteria"**

TX45 SAD Dose Escalation Plan



RPF= Renal Plasma Flo
*Cohorts F and G are option

1. As of Jan 18, 2024

Phase 1a Study: Preliminary Single Dose TX45 Pharmacokinetic/Pharmacodynamic Data (lowest dose)

TX45 Serum Concentrations from Phase 1a Subjects
Cohort A 0.3 mg/kg IV



Renal Plasma Flow in Phase 1a Subjects
TX45 Dosed on Day 1 - Cohort A 0.3 mg/kg IV



Based on Preliminary Data, We Anticipate Potentially Monthly Dosing at Optimal SC Dose

1. Placebo

Preclinical PK/PD from Acute RBF Model Informs Target Plasma Concentration Levels at Trough for Therapeutic Effect

RBF Model

Used to assess pharmacodynamic response to TX45 administration based on acute vasodilatory effects of relaxin, as measured by increased rat renal blood flow (RBF)

MCT Model

Used to assess the therapeutic anti inflammatory/anti-proliferative efficacy of TX45 in a rat model of pulmonary hypertension

The trough levels required for maximal efficacy in the MCT model fall between the EC_{70} and EC_{80} response in the RBF model



** The exposure in humans that falls between the EC70-80 are expected to be 3-fold lower than in rats given the greater potency of TX45 on human RXFP1 compared to rat RXFP1*

Summary of Projected TX45 Phase 2 Study Design



Significant Pharma Interest in Relaxin Tectonic has Potential Best-in-Class Molecule

Company	Format	Formulation	Expected Dosing Frequency	Population	Timing
TECTONIC Therapeutic	**Fc-Fusion** *Engineered for optimal PK, biodistribution, high [C] formulation*	**SubQ** *High [C] achievable*	**Q4 Weeks**	**Group 2 PH / HFpEF (enriched for CpcPH)**	**Data in 2026**
AstraZeneca	Fc-Fusion	SubQ	Q2 Weeks*	Group 2 PH / HFpEF *and* HFrEF	Start: Q1 2023 1° completion: Q2 2025
AstraZeneca	Small Molecule	PO	QD*	CHF	Start: Q2 2024 1° completion: Q4 2025
Lilly	h-Albumin-mAb-Fusion	SubQ *Injection site reactions*	Q Weekly*	HFpEF	Start: Q1 2023 1° completion: Q4 2025

* Based on dosing frequency in Phase 2 studies listed in clinical trials database

HHT Program

First-in- indication opportunity for 2nd most common genetic bleeding disorder

Hereditary Hemorrhagic Telangiectasia (HHT)

Autosomal Dominant Disease that Causes Abnormal Blood Vessel Formation

- Rare, autosomal dominant disease: ~ 75,000 patients in US
  - Mutations in the BMP9/10 pathway
- High degree of phenotypic variability (15-20% severe)
- Increased mortality risk

No currently approved therapies for HHT

Nosebleeds



Telangiectasias



Lung

AVMs



Liver

Telangiectasias



GI tract



Brain

FREQUENCY OF ABNORMAL HHT VESSELS

- **>95%** Nose (epistaxis)
- **>90%** Skin (Telangiectasia)
- **50%** Lungs (pulmonary AVMs*)
- **50%** Liver (hepatic AVMs)
- **20%** Gastrointestinal tract
- **10%** Brain (cerebral AVMs)

INCREASED FREQUENCY OF THE FOLLOWING

- Iron and transfusion dependent anemia (10-30% of patients)
- High output CHF 2nd to Liver AVM → liver transplant
- Stroke
- Brain abscesses and other deep tissue abscesses
- Venous thromboemboli (VTE)
- Pulmonary Hypertension
- Migraines

*AVM= arterial venous malformation

TECTONIC Therapeutic

Anti VEGF: Mouse HHT Model Predictive of Efficacy in Patients

ANTI-VEGF mAb SUPPRESSES AVM FORMATION, VISCERAL HEMORRHAGE IN HHT MODEL

ALK-1 Conditional Knock-Out
Wound-induced vascular response



Angiogenesis. 2014 Oct; 17(4): 823–830

ANTI-VEGF THERAPY REDUCES EPISTAXIS SEVERITY, IMPROVES HEM. PARAMETERS IN PATIENTS



- No rigorous clinical studies ever conducted – only evidence is from IITs
  - Patent expiration on anti-VEGF mab lowered incentive to investment in label expansion
  - Dose and Dosing interval not well explored
- Treating physicians concerned about side effects

Haematologica. 2021 Aug 1; 106(8): 2161–2169

A GPCR3 Antagonist Significantly Reduces AVMs and Retinal Vascular Density in Animal Model of HHT

Effects of anti-GPCR3 antagonist mAb in mouse HHT model generated by immunoblocking of BMP9 and BMP10[1,2]





1. Ruiz, S. et. al., Scientific Reports, 2016; 6:37366, doi: 10.1038/srep37366
2. Ruiz, S. et. al., J. Clin. Invest., 2020; 130(2):942–957, doi.org/10.1172/JCI127425

Projected HHT Development Program Overview



Summary

AVROBIO/Tectonic Merger Overview

Company Ticker	NASDAQ: TECX
Private Placement Investors	Major mutual fund, TAS Partners, 5AM Ventures, EcoR1 Capital, Polaris Partners, Farallon Capital (managed funds), Vida Ventures, Pags Group and other investors
Cash at Close	~$181 million[1]
Expected Cash Runway	Into Mid-2027
Reverse Stock Split:	1 for 12
Merger Close Date	6/20/2024

1. As of 6/20/24. Before final transaction expenses

TECTONIC Therapeutic

Uniquely Positioned to Deliver on Value Creating Milestones

Strong Balance Sheet Post Transaction	Pipeline of Uniquely Differentiated Assets	Accomplished Team World-leader Founders
>$181* Million ~3 year Runway	Multiple Inflection Points 2024, 2025, 2026, 2027	20 1st Approvals >$50B in Annual Sales
Well positioned to execute	Address important clinical problems, underserved patient populations	Leadership with Proven Track Record

*At transaction close (6/20/24), cash, cash equivalents and investments of approximately $181 million, before payment of final transaction-related expenses, is expected to fund current operational plans into mid-2027

Thank you

info@tectonictx.com
www.tectonictx.com
LinkedIn: TectonicTx